Denmark's Zealand Pharma H1 revenue, profit fall sharply

Zealand Pharma A/S

13/08/2026 06:11

Overview
Danish biotech firm's H1 2026 revenue fell sharply from prior year
Operating profit declined by more than 50% from prior year
Company launched $200 mln share buyback and monetized non-core asset for $100 mln

Outlook
Company maintains 2026 guidance for collaboration revenue at DKK 4.5 bln
Zealand Pharma expects 2026 operating expenses, excl. OOI, of DKK 2.7-3.3 bln

Result Drivers
PIPELINE PROGRESS - Co highlighted advancement of obesity drug candidates, including positive Phase 2 results for petrelintide and Phase 3 results for survodutide

Company press release: ID:nGNEbhF7pw

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
DKK 4.53 bln
 
H1 Operating Expenses
 
DKK 1.20 bln
 
H1 Operating Result
 
DKK 3.32 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Zealand Pharma A/S is DKK425.00, about 29.1% above its August 12 closing price of DKK329.20
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads
Aug 11 - Hims & Hers' shift to branded obesity drugs drives wider quarterly loss
Aug 10 - Eli Lilly's weight-loss pill secures first European nod in Britain
Aug 10 - Septerna Q2 revenue beats analyst estimates, driven by Novo Nordisk partnership

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)